Skip to content
Business websites
Business websites
Johnson & Johnson
J&J MedTech
Johnson & Johnson
J&J MedTech
Location
Language
English
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
Menu
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
265 Results
265 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Oncology
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
March 1, 2024
United States
Read more
Oncology
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
February 26, 2024
United States
Read more
Oncology
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
February 23, 2024
Belgium
Read more
Immunology
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
February 21, 2024
United States
Read more
Oncology
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
February 20, 2024
United States
Read more
Immunology
Johnson & Johnson highlights innovation in hemolytic disease of the fetus and newborn (HDFN) at the Society for Maternal-Fetal Medicine’s (SMFM) 2024 Pregnancy Meeting
February 9, 2024
United States
Read more
Oncology
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
February 8, 2024
Belgium
Read more
Immunology
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
February 7, 2024
United States
Read more
Immunology
Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)
February 5, 2024
United States
Read more
Oncology
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
January 30, 2024
United States
Read more
Previous
13 of 27
Next
Featured stories
Connecting the best of Health&Care
Read more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Read more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Read more
What is a gene mutation?
Read more
